Bristol-Myers Declines as Sales Drop Outweighs Pipeline

Bristol-Myers Squibb Co. fell the most in more than eight months after slow sales of existing products trumped investors’ interest in new cancer and hepatitis C drugs the company has in development.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.